Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update
~ Reports KEVEYIS® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter...